IL-6 promotes chemoresistance via upregulating CD36 mediated fatty acids uptake in acute myeloid leukemia

2022/03/25 by Yanjie Zhang, Hezhou Guo, He‐Zhou Guo +4 · 26 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer, Lipids, and Metabolism #Acute Myeloid Leukemia Research #Bone and Joint Diseases

paper · doi:10.1016/j.yexcr.2022.113112

Cited by

• T-Cell Responses and T-Cell-Based Therapy in Acute Myeloid Leukemia
• Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy. [europepmc]
• The cytokine network in acute myeloid leukemia. [europepmc]
• CD36-Fatty Acid-Mediated Metastasis via the Bidirectional Interactions of Cancer Cells and Macrophages. [europepmc]
• Role of CD36 in cancer progression, stemness, and targeting. [europepmc]
• Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier. [europepmc]
• Orchestral role of lipid metabolic reprogramming in T-cell malignancy. [europepmc]
• Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling. [europepmc]
• New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. [europepmc]
• AML alters bone marrow stromal cell osteogenic commitment via Notch signaling. [europepmc]
• Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity. [europepmc]
• CD36: The Bridge between Lipids and Tumors. [europepmc]
• Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression. [europepmc]
• Emerging targets in lipid metabolism for cancer therapy. [europepmc]
• A CD36-dependent non-canonical lipid metabolism program promotes immune escape and resistance to hypomethylating agent therapy in AML. [europepmc]
• Single-cell landscape of innate and acquired drug resistance in acute myeloid leukemia. [europepmc]
• Reprogrammed lipid metabolism in advanced resistant cancers: an upcoming therapeutic opportunity. [europepmc]
• Inflammation and Related Signaling Pathways in Acute Myeloid Leukemia. [europepmc]
• NVP-2, in combination with Orlistat, represents a promising therapeutic strategy for acute myeloid leukemia. [europepmc]
• Discovery and in vitro characterization of a human anti-CD36 scFv. [europepmc]
• Effect of Age, Sex and Season on Acute Myeloid Leukemia Clinical Characteristics: A Retrospective Study. [europepmc]
• CD36 as a marker of acute myeloid leukemia prognosis: A systematic review. [europepmc]
• Inflammatory signaling in the pathogenesis of acute myeloid leukemia. [europepmc]
• Identification of New CD36 Antagonists by Structure-Based Virtual Screening. [europepmc]
• Lipoprotein Metabolism in Hematological Malignancies: A Role in Shaping the Tumor Cell Microenvironment? [europepmc]
• The role of CD36 in renal and bladder cancer. [europepmc]